Hemispherx Biopharma Announces New Publication Enlarges The Understanding Of Ampligen® Safety Profile Across Diverse Animal Species And Focuses On The Unique TLR-3 Receptor/Ampligen(R) Interaction
Published: Apr 08, 2014
PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and Toxicological Species Responses to TLR-3 Activation" in the current issue of the American Journal of Pathology Vol. 184 (pages 1062-1072), 2014.
Help employers find you! Check out all the jobs and post your resume.